Skip to main content

Table 2 Survival influence of VIRMA in various cancers

From: Role of m6A methyltransferase component VIRMA in multiple human cancers (Review)

Cancer type Sample size Survival influence References
Breast cancer low-VIRMA (n = 528); high-VIRMA (n = 528) Worse OS [20]
low-VIRMA (n = 598); high-VIRMA (n = 472) Worse OS [42]
low-VIRMA (n = 611); high-VIRMA (n = 457) Worse RFS [42]
TCGA Worse OS [41]
Liver cancer 70 HCC patients Worse OS and DFS [29]
low-VIRMA (n = 182); high-VIRMA (n = 182) Worse OS [43]
374 HCC and 50 normal tissues from TCGA; 243 HCC and 202 normal tissues from ICGC Worse OS [45]
Kidney cancer 897 samples from 895 patients Worse OS and DFS [44]
Kidney renal clear cell carcinoma TCGA Better OS [41]
Kidney renal papillary cell carcinoma 289 kidney renal papillary cell carcinoma and 32 normal kidney samples from the TCGA database Better OS and DFS [49]
Prostate cancer TCGA + GTEx, 492 prostate adenocarcinoma and 152 adjacent normal specimens Worse DFS [58]
Gliomas 309 glioma patients from CGGA and 595 glioma patients from TCGA Worse OS [75]
Ovarian cancer 370 ovarian cancer tissues and 88 normal tissues from TCGA Worse OS [51]
Papillary thyroid carcinoma 499 tumor tissues and 58 normal thyroid carcinoma Better OS [52]
  1. TCGA: http://cancergenome.nih.gov/
  2. CGGA: www.cgga.org.cn
  3. ICGC: https://dcc.icgc.org/releases/current/Projects/LIRI-JP
  4. GTEx: https://gtexportal.org/